Britain and America have reached a significant trade agreement that will guarantee zero duties on UK drug exports going into the US market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has agreed to boost funding on pharmaceuticals through the National Health Service (NHS). This commitment guarantees that tariffs on these vital goods will stay at zero for a period of 36 months.
This deal comes after earlier statements to significantly raise import taxes on patented pharmaceutical imports, with potential rates mentioned up to double the cost.
"This arrangement between the UK reinforces the worldwide climate for new treatments and introduces long-overdue equity to U.S.–U.K. medicine commerce," a statement declared.
Economic Impact
Drugs constitute one of the UK's largest exports to the US, which is clearly the largest buyer for large UK drugmakers.
Trade data indicate that in the 12 months leading up to last September, the UK exported medicines totaling £11.1bn to the US. This figure made up 17.4% of total UK exports in that period.
"This deal secures jobs, increases investment and facilitates the UK to become a global hub for biotech and pharma," a minister remarked.
Key British Pledges
The agreement includes several notable commitments from the UK:
- Revised Affordability Limit: The UK will lift the price threshold at which it considers new medicines to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a aim to increase overall NHS spending on drugs from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Rebate Cap: The sum pharmaceutical firms must pay back to the NHS to prevent overspending will be limited at 15%. Last year, refunds topped 20%.
Industry Background
The pact follows a long-running row between the drug companies and the British authorities over medicine costs and regulatory access.
These tensions were intensified by arguments that American consumers were charged several times more for the same drugs than consumers in the other developed nations.
Over the last 18 months, several major drug company projects in the UK have been delayed or abandoned, while multi-billion-dollar expansions have been announced toward projects in the United States.
A senior figure stated that the NHS needed to increase expenditure on drugs, noting that its budget allocation on drugs had decreased as a share of its overall budget over the previous ten-year period.
